Proteomics‐Based Soluble Urokinase Plasminogen Activator Receptor Levels Are Associated With Adverse Cardiovascular Outcomes in the General Population: Insights From the UK Biobank

03 Jul 20264 min read1 viewsJournal Feed

GIST (Key Takeaways)

Journal of the American Heart Association, Volume 15, Issue 13 , July 7, 2026. Background. Elevated soluble urokinase plasminogen activator receptor (suPAR) levels are associated with inflammation, immune activation, and major adverse cardiovascular events in coronary artery disease.
Encoded by thePLAURgene, suPAR levels are influenced by the rs4760 genetic variant. Whether proteomics‐based suPAR levels predict adverse outcomes in the general population remains unknown. Methods.
Proteomics‐based suPAR levels were measured using the Olink Immunoassay in 33 963 UK Biobank participants without known coronary artery disease. Fine‐Gray and Cox proportional hazards models assessed associations between suPAR and major adverse cardiovascular events (primary outcome: cardiovascular mortality, nonfatal myocardial infarction, or stroke), cardiovascular mortality, and all‐cause mortality (secondary outcomes), after adjustment for demographic and clinical risk factors, hs‐CRP (high‐sensitivity C‐reactive protein), and the rs4760 variant. Incremental discrimination was evaluated using C‐statistics.
Results. Participants were aged 56.4 (SD, 8.2) years; 45% were men, and 93.4% were White. Over a median follow‐up of 14 years (476 177 person‐years), 10.7% experienced major adverse cardiovascular events, 2.6% experienced cardiovascular mortality, and 9.4% experienced all‐cause mortality.

Clinical Editorial

Journal of the American Heart Association published a clinical update in Cardiology on 03 Jul 2026.

The item focuses on Proteomics‐Based Soluble Urokinase Plasminogen Activator Receptor Levels Are Associated With Adverse Cardiovascular Outcomes in the General Population: Insights From the UK Biobank.

Review the original article for the full source wording and details.